Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic

  title={Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic},
  author={Paul E Keck Jr and Susan L. McElroy},
  journal={Expert Opinion on Investigational Drugs},
  pages={655 - 662}
  • P. Keck Jr, S. McElroy
  • Published 1 April 2003
  • Psychology, Medicine
  • Expert Opinion on Investigational Drugs
This paper reviews the clinical pharmacology, efficacy and safety of the novel antipsychotic drug aripiprazole. All published citations regarding aripiprazole were reviewed using a Medline® search (completed for citations through mid-year, 2002). In addition, abstracts from recent scientific meetings presenting data not yet published (nor peer-reviewed) were reviewed. Aripiprazole has a unique mechanism of action as a dopamine D2 partial agonist, serotonin 5-HT1A partial agonist and serotonin 5… 

Aripiprazole-induced persistent hiccup: a case report and review of the literature.

The case of aripiprazole-induced hiccup in a young inpatient at his first psychiatric admission is presented together with a review of the current literature about this topic.

When to start aripiprazole therapy in patients with bipolar mania

Aripiprazole is a third generation atypical antipsychotic with compelling evidence as a highly effective treatment option in the management of acute manic and mixed episodes of bipolar I disorders, and in the long-term prevention of manic relapses.

Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study

Findings may help physicians in choosing relevant ways to use aripiprazole and highlight areas where more research is needed to widen the evidence base.

Utility of Combined Treatment with Antipsychotic and Antidepressant Drugs: Scientific Rationales and Clinical Implications

The results propose that adjunct NET inhibition by reboxetine may be used to augment the antipsychotic effect of low doses of olanzapine in schizophrenia and improve the effect on negative symptoms and cognitive impairments.

Aripiprazole: in acute mania associated with bipolar I disorder.

Aripiprazole had a rapid onset of action and was effective in the treatment of patients with bipolar I disorder experiencing an acute manic or mixed episode, and demonstrated superior effectiveness to haloperidol in a 12-week comparative trial.

Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder.

Oral aripiprazole monotherapy was at least as effective as haloperidol monotherapy in terms of improving symptoms of mania, but had the advantage of a lower incidence of some adverse events, such as extrapyramidal symptom-related adverse events.

Mode of action of asenapine vs. other antipsychotic drugs : an experimental analysis

The data propose that the α2:D2 ratio by risperidone is indeed not optimal and that its antipsychotic-like efficiency can be enhanced by adjunctive treatment with an α2- adrenoceptor antagonist, e.g. idazoxan, allowing for reduced dosage and a subsequent reduced EPS liability, yet with maintained efficacy.

A safety evaluation of aripiprazole for treating schizophrenia during pregnancy and puerperium

  • S. Gentile
  • Medicine
    Expert opinion on drug safety
  • 2014
If used during late pregnancy, some signals exist suggesting that ARI may worse neonatal outcomes, hence, clinicians should consider withdrawing the drug before the last month of pregnancy to reduce the risks of neonatal complications.


Understanding the individual receptor activity of each agent can not only aid in the understanding of the differential clinical actions of the various medications but also guide us in the clinical decision-making process.



Ziprasidone: a new atypical antipsychotic

This paper reviews the clinical pharmacology, efficacy and safety of the new atypical antipsychotic, ziprasidone. All published citations regarding ziprasidone were retrieved and reviewed using a

Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors

These results, together with previous studies demonstrating partial agonist activity at serotonin 5-hydroxytryptamine (5-HT)1A receptors and antagonist activity at 5-HT2A receptors, support the identification of aripiprazole as a dopamine-serotonin system stabilizer.

Role of serotonin in the action of atypical antipsychotic drugs.

  • H. Meltzer
  • Psychology, Medicine
    Clinical neuroscience
  • 1995
The basis for the superior ability of clozapine to treat negative symptoms and enhance cognitive function compared to typical neuroleptic drugs in schizophrenic patients has not yet been ascertained, but there is evidence that its effect on 5-HT2A, D2, or D4 receptors may be important.

The new generation of antipsychotic drugs: how atypical are they?

  • J. Goldstein
  • Psychology, Medicine
    The international journal of neuropsychopharmacology
  • 2000
The pharmacological actions that contribute to the unique features of clozapine are reviewed, focusing on receptor profile and activity in animal models used for evaluations of antipsychotic activity and EPS.

Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes

Neurobiological mechanisms involved in antidepressant therapies.

During prolonged administration with a SSRI, three feedback systems become desensitized and their regulatory effects on serotonergic neurotransmission are weakened or lost, which may explain the latency of antidepressant action seen with these drugs in humans.

Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action.

  • S. Stahl
  • Psychology
    The Journal of clinical psychiatry
  • 2001
The ideal mix of dopamine-2 (D 2 ) receptor stimulation and D 2 receptor blockade may stabilize the dopamine system and reduce psychosis without creating extrapyramidal motor side effects, resulting in a novel antipsychotic that does not produceMotor side effects.